Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

SABCS 2008 /
New data from the BIG 1-98 breast cancer trial

10th - 14th Dec 2008

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.12.08
Views: 17065
Rating:

Professor Henning Mouridsen, Copenhagen University Hospital

Professor Mouridsen, the BIG 1-98 Lead Investigator at Copenhagen University Hospital, discusses findings and new data from the BIG 1-98 breast cancer trial, announced at the 31st San Antonio Breast Cancer Symposium. "Post menopausal patients with primary hormone receptor positive disease should now be offered up front letrozole rather than tamoxifen"

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation